ES2163405T3 - Virus recombinantes que comprenden sitios de escision proteoliticos artificiales. - Google Patents

Virus recombinantes que comprenden sitios de escision proteoliticos artificiales.

Info

Publication number
ES2163405T3
ES2163405T3 ES93900925T ES93900925T ES2163405T3 ES 2163405 T3 ES2163405 T3 ES 2163405T3 ES 93900925 T ES93900925 T ES 93900925T ES 93900925 T ES93900925 T ES 93900925T ES 2163405 T3 ES2163405 T3 ES 2163405T3
Authority
ES
Spain
Prior art keywords
recombinant viruses
competing
replication
scision
proteolitic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93900925T
Other languages
English (en)
Inventor
Mark Feinberg
Raul Andino
Carolyn Louise Weeks-Levy
Patricia Anne Reilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research, American Cyanamid Co filed Critical Whitehead Institute for Biomedical Research
Application granted granted Critical
Publication of ES2163405T3 publication Critical patent/ES2163405T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VIRUS RECOMBINANTES QUE COMPETEN A LA REPLICACION, PARTICULARMENTE POLIOVIRUS RECOMBINANTES QUE COMPETEN A LA REPLICACION, QUE INCLUYEN (1) SECUENCIAS DE ACIDO NUCLEICO EXOGENO QUE CODIFICA UN POLIPEPTIDO EXOGENO Y (2) UNA SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA UN EMPLAZAMIENTO DE SEGMENTACION PROTEOLITICO ARTIFICIAL PARA UNA PROTEASA CELULAR O VIRAL QUE PROCESE (DIVIDA) PROTEOLITICAMENTE LA PROTEINA PRECURSORA PRODUCIDA POR EL VIRUS PADRE Y USOS PARA ESTO. EL PRECURSOR RECOMBINANTE ES SEGMENTADO EN EL ORDEN HABITUAL DE PROTEINAS CONSTITUYENTES, LIBERANDO EL POLIPEPTIDO EXOGENO. LOS VIRUS RECOMBINANTES QUE COMPETEN A LA REPLICACION SON UTILES COMO VACUNAS CONTRA INFECCIONES BACTERIANAS, VIRICAS, FUNGALES Y DE LEVADURA, ENFERMEDADES PARASITARIAS, CANCER Y ALERGIAS.
ES93900925T 1991-12-06 1992-12-04 Virus recombinantes que comprenden sitios de escision proteoliticos artificiales. Expired - Lifetime ES2163405T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80489391A 1991-12-06 1991-12-06
US94779092A 1992-09-18 1992-09-18
PCT/US1992/010543 WO1993011251A1 (en) 1991-12-06 1992-12-04 Recombinant viruses comprising artificial proteolytic cleavage site

Publications (1)

Publication Number Publication Date
ES2163405T3 true ES2163405T3 (es) 2002-02-01

Family

ID=27122734

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93900925T Expired - Lifetime ES2163405T3 (es) 1991-12-06 1992-12-04 Virus recombinantes que comprenden sitios de escision proteoliticos artificiales.

Country Status (20)

Country Link
EP (1) EP0672157B1 (es)
JP (1) JPH07502403A (es)
KR (1) KR100272419B1 (es)
CN (1) CN1055726C (es)
AT (1) ATE206762T1 (es)
AU (1) AU674134B2 (es)
CA (1) CA2123804A1 (es)
CZ (1) CZ127394A3 (es)
DE (1) DE69232122T2 (es)
DK (1) DK0672157T3 (es)
ES (1) ES2163405T3 (es)
FI (1) FI942623A (es)
HU (1) HUT67346A (es)
IL (1) IL104003A0 (es)
MX (1) MX9206981A (es)
NO (1) NO942075L (es)
NZ (1) NZ246276A (es)
PT (1) PT672157E (es)
TW (1) TW403784B (es)
WO (1) WO1993011251A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716466B2 (en) * 1995-09-27 2000-02-24 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
FI20075063A0 (fi) 2007-02-01 2007-02-01 Vactech Oy Allergisen herkistymisen estäminen
WO2019179345A1 (en) 2018-03-19 2019-09-26 Boehringer Ingelheim (China) Investment Co., Ltd. Recombinant virus capable of stably expressing target proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293591C (en) * 1985-01-11 1991-12-24 Charles A. Kettner Peptide substrates for detecting virus-specified protease activity
EP0321973B1 (de) * 1987-12-23 1993-11-03 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Expression der viral kodierten Protease P2A des HRV2
EP0406267A1 (en) * 1988-02-26 1991-01-09 Biosource Genetics Corporation Non-nuclear chromosomal transformation
DD275259A1 (de) * 1988-08-30 1990-01-17 Akad Wissenschaften Ddr Verfahren zur konstruktion eines neuen expressionsvektors
WO1990011359A1 (en) * 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
CA2055613A1 (en) * 1989-05-31 1990-12-01 Jeffrey W. Almond Poliovirus chimaeras
GB8912496D0 (en) * 1989-05-31 1989-07-19 Medical Res Council Vaccines
DE69033006T2 (de) * 1990-05-28 1999-09-23 Univ Osaka Res Found Herstellungsverfahren für ein plasmid mit fähigkeiten zu expression und prozessierung nach translation eines retroviralen gens, so erhaltenes plasmid und dessen expressionsprodukt
JPH05506999A (ja) * 1990-08-28 1993-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスプロティナーゼの活性をモニターするためのテスト系

Also Published As

Publication number Publication date
HU9401689D0 (en) 1994-09-28
ATE206762T1 (de) 2001-10-15
MX9206981A (es) 1994-08-31
IL104003A0 (en) 1993-05-13
CA2123804A1 (en) 1993-06-10
JPH07502403A (ja) 1995-03-16
DE69232122T2 (de) 2002-05-16
KR100272419B1 (ko) 2001-02-01
WO1993011251A1 (en) 1993-06-10
NO942075D0 (no) 1994-06-03
DK0672157T3 (da) 2001-12-03
CZ127394A3 (en) 1995-11-15
EP0672157A1 (en) 1995-09-20
CN1075334A (zh) 1993-08-18
CN1055726C (zh) 2000-08-23
AU674134B2 (en) 1996-12-12
NZ246276A (en) 1996-08-27
DE69232122D1 (de) 2001-11-15
NO942075L (no) 1994-08-03
EP0672157B1 (en) 2001-10-10
TW403784B (en) 2000-09-01
AU3242493A (en) 1993-06-28
FI942623A (fi) 1994-07-21
HUT67346A (en) 1995-03-28
KR950700421A (ko) 1995-01-16
FI942623A0 (fi) 1994-06-03
PT672157E (pt) 2002-04-29

Similar Documents

Publication Publication Date Title
AU539535B2 (en) Recombinant dna molecules
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
FI932678A (fi) Pao alfavirus baserande dna expressionssystem
ATE289348T1 (de) Methoden zur erhöhung der produktion von viralen impstoffen in zellkultur durch unterdrückung von interferon
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ATE230798T1 (de) Rekombinanter herpes simplex gb-gd-impfstoff
FI864624A (fi) Bombyx morin nuclear polyhedrosis -yhdistelmävirus ja menetelmiä proteiinien valmistamiseksi tätä käyttäen
ES2127294T3 (es) Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
GB8914968D0 (en) Production of virus and purification of viral envelope proteins for vaccine use
WO2001016163A3 (en) Peptide mixture and vaccine against a chronic viral infection
ES2163405T3 (es) Virus recombinantes que comprenden sitios de escision proteoliticos artificiales.
ES2111570T3 (es) Aislamiento y purificacion de la proteina de agente tensioactivo pulmonar.
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
DE69011122D1 (de) Rubella-e1 und c peptide.
ES2080024B1 (es) Vacuna subunitaria recombinante contra la enfermedad hemorragica virica de los conejos.
RU94030478A (ru) Рекомбинантный вирус, способ его получения, способ иммунизации, способ получения протеина, вакцинная композиция, применение рекомбинантного вируса
AR248047A1 (es) Procedimiento para la preparacion de una vacuna a base de virus del herpes bovina modificado tipo 1.
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
JPS6485092A (en) Production of protein

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 672157

Country of ref document: ES